FY2024 EPS Estimates for Genfit Reduced by Leerink Partnrs

Genfit S.A. (NASDAQ:GNFT - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of Genfit in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn $0.60 per share for the year, down from their prior forecast of $0.61. The consensus estimate for Genfit's current full-year earnings is $0.95 per share. Leerink Partnrs also issued estimates for Genfit's FY2029 earnings at ($0.53) EPS.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $13.00 price target on shares of Genfit in a research note on Friday.

Genfit Stock Down 2.1 %

GNFT stock traded down $0.09 during trading on Thursday, reaching $3.91. 741 shares of the company were exchanged, compared to its average volume of 10,394. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61. The stock's 50 day moving average price is $3.75 and its 200 day moving average price is $4.43. Genfit has a 52-week low of $3.35 and a 52-week high of $6.42.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.